145
Views
3
CrossRef citations to date
0
Altmetric
Original Research

A Retrospective Data Review Confirms That Topical Preservative-Free Hydrocortisone Improves Inflammation in Dry Eye Disease

ORCID Icon, , , , &
Pages 3691-3697 | Published online: 30 Oct 2020

References

  • Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802–812. doi:10.1016/j.jtos.2017.08.003
  • Baudouin C, Irkec M, Messmer EM, et al. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting. Acta Ophthalmol. 2018;96(2):111–119. doi:10.1111/aos.13436
  • Bron AJ, Yokoi N, Gafney E, Tiffany JM. Predicted phenotypes of dry eye: proposed consequences of its natural history. Ocul Surf. 2009;7(2):78–92. doi:10.1016/S1542-0124(12)70299-9
  • Lambiase A, Micera A, Sacchetti M, Cortes M, Mantelli F, Bonini S. Alterations of tear neuromediators in dry eye disease. Arch Ophthalmol. 2011;129(8):981–986. doi:10.1001/archophthalmol.2011.200
  • Willcox MDP, Argüeso P, Georgiev GA, et al. TFOS DEWS II tear film report. Ocul Surf. 2017;15(3):366–403. doi:10.1016/j.jtos.2017.03.006
  • Zhang X, Qu Y, He X, et al. Dry eye management: targeting the ocular surface microenvironment. Int J Mol Sci. 2017;18(7):1398. doi:10.3390/ijms18071398
  • Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71–81;quiz 2.
  • Cutolo CA, Barabino S, Bonzano C, Traverso CE. The use of topical corticosteroids for treatment of dry eye syndrome. Ocul Immunol Inflamm. 2019;27(2):266–275. doi:10.1080/09273948.2017.1341988
  • Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. 2019;11:2515841419870366. doi:10.1177/2515841419870366
  • Hamard H, Schmitt C, Plazonnet B, Le Douarec JS. Study of the ocular penetration of dexamethasone. [Etude de la pénétration oculaire de la déxamethasone.] In: Demailly P, Hamard H, Luton JP, editors. Oeil et cortisone. Paris: Masson; 1975:33–84.
  • McGhee CN. Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol. 1992;76(11):681–684. doi:10.1136/bjo.76.11.681
  • Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012;47(2):66–80. doi:10.1159/000328630
  • Kallab M, Szegedi S, Hommer N, et al. Topical low dose preservative-free hydrocortisone reduces signs and symptoms in patients with chronic dry eye: a randomized clinical trial. Adv Ther. 2020;37(1):329–341. doi:10.1007/s12325-019-01137-8
  • Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118(5):615–621.
  • Zhuang H, Zhou X, Xu J. A novel method for pachymetry mapping of human precorneal tear film using Pentacam with fluorescein. Invest Ophthalmol Vis Sci. 2010;51(1):156–159. doi:10.1167/iovs.08-3265
  • Kang NH, Park YG, Jun RM. Measurement of Precorneal tear film using scheimpflug camera and relationship with parameters for dry eye. J Korean Ophthalmol Soc. 2015;56(11):1699–1705. doi:10.3341/jkos.2015.56.11.1699
  • Fariselli C, Giannaccare G, Fresina M, Versura P. Trehalose/hyaluronate eyedrop effects on ocular surface inflammatory markers and mucin expression in dry eye patients. Clin Ophthalmol. 2018;12:1293–1300. doi:10.2147/OPTH.S174290
  • Mediately. Softacort 3,35 mg/ml kapi za oko, otopina u jednodoznom spremniku. Available from: https://mediately.co/hr/drugs/98sHG12OKofkQVVLgKqws8me2mX/softacort-3-35-mg-ml-kapi-za-oko-otopina-u-jednodoznom-spremniku. [Serbian]. Accessed August 15, 2020.
  • Sullivan DA, Rocha EM, Aragona P, et al. TFOS DEWS II sex, gender, and hormones report. Ocul Surf. 2017;15(3):284–333. doi:10.1016/j.jtos.2017.04.001
  • Farrand KF, Fridman M, Stillman IO, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90–98.
  • Su T-Y, Ho W-T, Chiang S-C, Lu C-Y, Chiang HK, Chang S-W. Infrared thermography in the evaluation of meibomian gland dysfunction. J Formos Med Assoc. 2017;116(7):554–559. doi:10.1016/j.jfma.2016.09.012
  • Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 2011;151(5):792–8e1. doi:10.1016/j.ajo.2010.10.032
  • Messmer EM, von Lindenfels V, Garbe A, Kampik A. Matrix metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassay. Ophthalmology. 2016;123(11):2300–2308. doi:10.1016/j.ophtha.2016.07.028
  • Arita R. Meibography: a Japanese perspective. Invest Ophthalmol Vis Sci. 2018;59(14):DES48–DES55. doi:10.1167/iovs.17-23631
  • Tiffany JM, Winter N, Bliss G. Tear film stability and tear surface tension. Curr Eye Res. 1989;8(5):507–515. doi:10.3109/02713688909000031
  • Tiffany JM. Surface tension in tears. Arch Soc Esp Oftalmol. 2006;81(7):363–366.
  • Tsubota K. Short tear film breakup time-type dry eye. Invest Ophthalmol Vis Sci. 2018;59(14):DES64–DES70. doi:10.1167/iovs.17-23746
  • Aragona P, Giannaccare G, Mencucci R, Rubino P, Cantera E, Rolando M. Modern approach to the treatment of dry eye, a complex multifactorial disease: a P.I.C.A.S.S.O. board review. Br J Ophthalmol. 2020:bjophthalmol-2019-315747. doi:10.1136/bjophthalmol-2019-315747